Loading…

Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents

Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the w...

Full description

Saved in:
Bibliographic Details
Published in:Antibiotics (Basel) 2022-10, Vol.11 (10), p.1431
Main Authors: Arrigoni, Roberto, Ballini, Andrea, Topi, Skender, Bottalico, Lucrezia, Jirillo, Emilio, Santacroce, Luigi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163
cites cdi_FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163
container_end_page
container_issue 10
container_start_page 1431
container_title Antibiotics (Basel)
container_volume 11
creator Arrigoni, Roberto
Ballini, Andrea
Topi, Skender
Bottalico, Lucrezia
Jirillo, Emilio
Santacroce, Luigi
description Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the world, thus, allowing TB to spread around the world. The stringent response is demonstrated by Mtb strains in order to survive under hostile circumstances, even including exposure to antibiotics. The stringent response is mediated by alarmones, which regulate bacterial replication, transcription and translation. Moreover, the Mtb cell wall contributes to the mechanism of antibiotic resistance along with efflux pump activation and biofilm formation. Immunity over the course of TB is managed by M1-macrophages and M2-macrophages, which regulate the immune response against Mtb infection, with the former exerting inflammatory reactions and the latter promoting an anti-inflammatory profile. T helper 1 cells via secretion of interferon (IFN)-gamma, play a protective role in the course of TB, while T regulatory cells secreting interleukin 10, are anti-inflammatory. Alternative therapeutic options against TB require further discussion. In view of the increasing number of MDR Mtb strains, attempts to replace antibiotics with natural and biological products have been object of intensive investigation. Therefore, in this review the anti-Mtb effects exerted by probiotics, polyphenols, antimicrobial peptides and IFN-gamma will be discussed. All the above cited compounds are endowed either with direct antibacterial activity or with anti-inflammatory and immunomodulating characteristics.
doi_str_mv 10.3390/antibiotics11101431
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7e462df6cf154791ad0c4f7e1b001372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7e462df6cf154791ad0c4f7e1b001372</doaj_id><sourcerecordid>2728412444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163</originalsourceid><addsrcrecordid>eNptkt1qFTEQxxdRsNQ-QW8C3nizmq_dJDfCsdhaqFqkvQ7ZfBxzyNnUJFvoY_SNndNTSivmJjOZ__xmMkzXHRP8kTGFP5m5xSnmFm0lhGDCGXnVHVAsVD8ySV8_s992R7VuMBxFmMTyoLtfPWWjX77G2sxsPWoZfb-zeTK2-RKXLWrL5ItdUgYJMrNDl7l5SDUJXVePckA_TFsKuLvgl5hTXkcL7mXJbrENkipaJaDNpsVbj3Z1-2c1QLpaA7G-694Ek6o_erwPu-vTr1cn3_qLn2fnJ6uL3nI8tp4KMXBmxEC59M4yPropCEVFENNEBjmMEoPJJxN8cJg4IQhlWFJnOcVkZIfd-Z7rstnomxK3ptzpbKJ-eMhlrU2BsSSvhecjdWG0gQxcKGIctjwITyaMCRMUWJ_3rJtl2kI38A8YxQvoy8gcf-t1vtVqUJJyAYAPj4CS_yy-Nr2N1fqUzOzzUjUVVA1EcKlA-v4f6SYvMNX0oJKcUM45qNheZUuutfjw1AzBerc2-j9rw_4C8C27nA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2728412444</pqid></control><display><type>article</type><title>Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Arrigoni, Roberto ; Ballini, Andrea ; Topi, Skender ; Bottalico, Lucrezia ; Jirillo, Emilio ; Santacroce, Luigi</creator><creatorcontrib>Arrigoni, Roberto ; Ballini, Andrea ; Topi, Skender ; Bottalico, Lucrezia ; Jirillo, Emilio ; Santacroce, Luigi</creatorcontrib><description>Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the world, thus, allowing TB to spread around the world. The stringent response is demonstrated by Mtb strains in order to survive under hostile circumstances, even including exposure to antibiotics. The stringent response is mediated by alarmones, which regulate bacterial replication, transcription and translation. Moreover, the Mtb cell wall contributes to the mechanism of antibiotic resistance along with efflux pump activation and biofilm formation. Immunity over the course of TB is managed by M1-macrophages and M2-macrophages, which regulate the immune response against Mtb infection, with the former exerting inflammatory reactions and the latter promoting an anti-inflammatory profile. T helper 1 cells via secretion of interferon (IFN)-gamma, play a protective role in the course of TB, while T regulatory cells secreting interleukin 10, are anti-inflammatory. Alternative therapeutic options against TB require further discussion. In view of the increasing number of MDR Mtb strains, attempts to replace antibiotics with natural and biological products have been object of intensive investigation. Therefore, in this review the anti-Mtb effects exerted by probiotics, polyphenols, antimicrobial peptides and IFN-gamma will be discussed. All the above cited compounds are endowed either with direct antibacterial activity or with anti-inflammatory and immunomodulating characteristics.</description><identifier>ISSN: 2079-6382</identifier><identifier>EISSN: 2079-6382</identifier><identifier>DOI: 10.3390/antibiotics11101431</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Antibacterial activity ; Antibiotic resistance ; Antibiotics ; Antimicrobial agents ; Antimicrobial peptides ; Bacteria ; Biofilms ; Biological products ; Cell walls ; Cytokines ; DNA methylation ; Drug resistance ; Efflux ; Growth factors ; HIV ; Human immunodeficiency virus ; Immune response ; Immune system ; immunity ; Immunoregulation ; Infections ; Infectious diseases ; Inflammation ; Interferon ; Interleukin 10 ; Isoniazid ; Lymphocytes T ; Macrophages ; Microbiota ; multi-drug resistant Mycobacterium tuberculosis strains ; Multidrug resistance ; Mycobacterium tuberculosis ; Natural products ; Peptides ; Polyphenols ; Probiotics ; Pyrazinamide ; Review ; Rifampin ; Strains (organisms) ; Stringent response ; Tuberculosis ; Tumor necrosis factor-TNF ; γ-Interferon</subject><ispartof>Antibiotics (Basel), 2022-10, Vol.11 (10), p.1431</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163</citedby><cites>FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163</cites><orcidid>0000-0001-5671-8124 ; 0000-0001-8758-1415 ; 0000-0003-4176-3939 ; 0000-0001-5361-4346</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2728412444/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2728412444?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids></links><search><creatorcontrib>Arrigoni, Roberto</creatorcontrib><creatorcontrib>Ballini, Andrea</creatorcontrib><creatorcontrib>Topi, Skender</creatorcontrib><creatorcontrib>Bottalico, Lucrezia</creatorcontrib><creatorcontrib>Jirillo, Emilio</creatorcontrib><creatorcontrib>Santacroce, Luigi</creatorcontrib><title>Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents</title><title>Antibiotics (Basel)</title><description>Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the world, thus, allowing TB to spread around the world. The stringent response is demonstrated by Mtb strains in order to survive under hostile circumstances, even including exposure to antibiotics. The stringent response is mediated by alarmones, which regulate bacterial replication, transcription and translation. Moreover, the Mtb cell wall contributes to the mechanism of antibiotic resistance along with efflux pump activation and biofilm formation. Immunity over the course of TB is managed by M1-macrophages and M2-macrophages, which regulate the immune response against Mtb infection, with the former exerting inflammatory reactions and the latter promoting an anti-inflammatory profile. T helper 1 cells via secretion of interferon (IFN)-gamma, play a protective role in the course of TB, while T regulatory cells secreting interleukin 10, are anti-inflammatory. Alternative therapeutic options against TB require further discussion. In view of the increasing number of MDR Mtb strains, attempts to replace antibiotics with natural and biological products have been object of intensive investigation. Therefore, in this review the anti-Mtb effects exerted by probiotics, polyphenols, antimicrobial peptides and IFN-gamma will be discussed. All the above cited compounds are endowed either with direct antibacterial activity or with anti-inflammatory and immunomodulating characteristics.</description><subject>Antibacterial activity</subject><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial peptides</subject><subject>Bacteria</subject><subject>Biofilms</subject><subject>Biological products</subject><subject>Cell walls</subject><subject>Cytokines</subject><subject>DNA methylation</subject><subject>Drug resistance</subject><subject>Efflux</subject><subject>Growth factors</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Immune response</subject><subject>Immune system</subject><subject>immunity</subject><subject>Immunoregulation</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Inflammation</subject><subject>Interferon</subject><subject>Interleukin 10</subject><subject>Isoniazid</subject><subject>Lymphocytes T</subject><subject>Macrophages</subject><subject>Microbiota</subject><subject>multi-drug resistant Mycobacterium tuberculosis strains</subject><subject>Multidrug resistance</subject><subject>Mycobacterium tuberculosis</subject><subject>Natural products</subject><subject>Peptides</subject><subject>Polyphenols</subject><subject>Probiotics</subject><subject>Pyrazinamide</subject><subject>Review</subject><subject>Rifampin</subject><subject>Strains (organisms)</subject><subject>Stringent response</subject><subject>Tuberculosis</subject><subject>Tumor necrosis factor-TNF</subject><subject>γ-Interferon</subject><issn>2079-6382</issn><issn>2079-6382</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkt1qFTEQxxdRsNQ-QW8C3nizmq_dJDfCsdhaqFqkvQ7ZfBxzyNnUJFvoY_SNndNTSivmJjOZ__xmMkzXHRP8kTGFP5m5xSnmFm0lhGDCGXnVHVAsVD8ySV8_s992R7VuMBxFmMTyoLtfPWWjX77G2sxsPWoZfb-zeTK2-RKXLWrL5ItdUgYJMrNDl7l5SDUJXVePckA_TFsKuLvgl5hTXkcL7mXJbrENkipaJaDNpsVbj3Z1-2c1QLpaA7G-694Ek6o_erwPu-vTr1cn3_qLn2fnJ6uL3nI8tp4KMXBmxEC59M4yPropCEVFENNEBjmMEoPJJxN8cJg4IQhlWFJnOcVkZIfd-Z7rstnomxK3ptzpbKJ-eMhlrU2BsSSvhecjdWG0gQxcKGIctjwITyaMCRMUWJ_3rJtl2kI38A8YxQvoy8gcf-t1vtVqUJJyAYAPj4CS_yy-Nr2N1fqUzOzzUjUVVA1EcKlA-v4f6SYvMNX0oJKcUM45qNheZUuutfjw1AzBerc2-j9rw_4C8C27nA</recordid><startdate>20221018</startdate><enddate>20221018</enddate><creator>Arrigoni, Roberto</creator><creator>Ballini, Andrea</creator><creator>Topi, Skender</creator><creator>Bottalico, Lucrezia</creator><creator>Jirillo, Emilio</creator><creator>Santacroce, Luigi</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5671-8124</orcidid><orcidid>https://orcid.org/0000-0001-8758-1415</orcidid><orcidid>https://orcid.org/0000-0003-4176-3939</orcidid><orcidid>https://orcid.org/0000-0001-5361-4346</orcidid></search><sort><creationdate>20221018</creationdate><title>Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents</title><author>Arrigoni, Roberto ; Ballini, Andrea ; Topi, Skender ; Bottalico, Lucrezia ; Jirillo, Emilio ; Santacroce, Luigi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibacterial activity</topic><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial peptides</topic><topic>Bacteria</topic><topic>Biofilms</topic><topic>Biological products</topic><topic>Cell walls</topic><topic>Cytokines</topic><topic>DNA methylation</topic><topic>Drug resistance</topic><topic>Efflux</topic><topic>Growth factors</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Immune response</topic><topic>Immune system</topic><topic>immunity</topic><topic>Immunoregulation</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Inflammation</topic><topic>Interferon</topic><topic>Interleukin 10</topic><topic>Isoniazid</topic><topic>Lymphocytes T</topic><topic>Macrophages</topic><topic>Microbiota</topic><topic>multi-drug resistant Mycobacterium tuberculosis strains</topic><topic>Multidrug resistance</topic><topic>Mycobacterium tuberculosis</topic><topic>Natural products</topic><topic>Peptides</topic><topic>Polyphenols</topic><topic>Probiotics</topic><topic>Pyrazinamide</topic><topic>Review</topic><topic>Rifampin</topic><topic>Strains (organisms)</topic><topic>Stringent response</topic><topic>Tuberculosis</topic><topic>Tumor necrosis factor-TNF</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arrigoni, Roberto</creatorcontrib><creatorcontrib>Ballini, Andrea</creatorcontrib><creatorcontrib>Topi, Skender</creatorcontrib><creatorcontrib>Bottalico, Lucrezia</creatorcontrib><creatorcontrib>Jirillo, Emilio</creatorcontrib><creatorcontrib>Santacroce, Luigi</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Antibiotics (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arrigoni, Roberto</au><au>Ballini, Andrea</au><au>Topi, Skender</au><au>Bottalico, Lucrezia</au><au>Jirillo, Emilio</au><au>Santacroce, Luigi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents</atitle><jtitle>Antibiotics (Basel)</jtitle><date>2022-10-18</date><risdate>2022</risdate><volume>11</volume><issue>10</issue><spage>1431</spage><pages>1431-</pages><issn>2079-6382</issn><eissn>2079-6382</eissn><abstract>Background: Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). TB treatment is based on the administration of three major antibiotics: isoniazid, rifampicin, and pyrazinamide. However, multi-drug resistant (MDR) Mtb strains are increasing around the world, thus, allowing TB to spread around the world. The stringent response is demonstrated by Mtb strains in order to survive under hostile circumstances, even including exposure to antibiotics. The stringent response is mediated by alarmones, which regulate bacterial replication, transcription and translation. Moreover, the Mtb cell wall contributes to the mechanism of antibiotic resistance along with efflux pump activation and biofilm formation. Immunity over the course of TB is managed by M1-macrophages and M2-macrophages, which regulate the immune response against Mtb infection, with the former exerting inflammatory reactions and the latter promoting an anti-inflammatory profile. T helper 1 cells via secretion of interferon (IFN)-gamma, play a protective role in the course of TB, while T regulatory cells secreting interleukin 10, are anti-inflammatory. Alternative therapeutic options against TB require further discussion. In view of the increasing number of MDR Mtb strains, attempts to replace antibiotics with natural and biological products have been object of intensive investigation. Therefore, in this review the anti-Mtb effects exerted by probiotics, polyphenols, antimicrobial peptides and IFN-gamma will be discussed. All the above cited compounds are endowed either with direct antibacterial activity or with anti-inflammatory and immunomodulating characteristics.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/antibiotics11101431</doi><orcidid>https://orcid.org/0000-0001-5671-8124</orcidid><orcidid>https://orcid.org/0000-0001-8758-1415</orcidid><orcidid>https://orcid.org/0000-0003-4176-3939</orcidid><orcidid>https://orcid.org/0000-0001-5361-4346</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2079-6382
ispartof Antibiotics (Basel), 2022-10, Vol.11 (10), p.1431
issn 2079-6382
2079-6382
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7e462df6cf154791ad0c4f7e1b001372
source Publicly Available Content Database; PubMed Central
subjects Antibacterial activity
Antibiotic resistance
Antibiotics
Antimicrobial agents
Antimicrobial peptides
Bacteria
Biofilms
Biological products
Cell walls
Cytokines
DNA methylation
Drug resistance
Efflux
Growth factors
HIV
Human immunodeficiency virus
Immune response
Immune system
immunity
Immunoregulation
Infections
Infectious diseases
Inflammation
Interferon
Interleukin 10
Isoniazid
Lymphocytes T
Macrophages
Microbiota
multi-drug resistant Mycobacterium tuberculosis strains
Multidrug resistance
Mycobacterium tuberculosis
Natural products
Peptides
Polyphenols
Probiotics
Pyrazinamide
Review
Rifampin
Strains (organisms)
Stringent response
Tuberculosis
Tumor necrosis factor-TNF
γ-Interferon
title Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T23%3A57%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20Resistance%20to%20Mycobacterium%20tuberculosis%20and%20Potential%20Use%20of%20Natural%20and%20Biological%20Products%20as%20Alternative%20Anti-Mycobacterial%20Agents&rft.jtitle=Antibiotics%20(Basel)&rft.au=Arrigoni,%20Roberto&rft.date=2022-10-18&rft.volume=11&rft.issue=10&rft.spage=1431&rft.pages=1431-&rft.issn=2079-6382&rft.eissn=2079-6382&rft_id=info:doi/10.3390/antibiotics11101431&rft_dat=%3Cproquest_doaj_%3E2728412444%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-277543a75248edc346dbf7927f7bb1585680f7b4bafefd01d77123082dc420163%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2728412444&rft_id=info:pmid/&rfr_iscdi=true